No Panic At Newron Over Delayed Schizophrenia Drug Trial
Although the US FDA raised concerns about a rat toxicity trial, causing shares to slide, Italy's Newron believes the trial delay for schizophrenia therapy evenamide is just a blip.
You may also be interested in...
First new chemical entity for Parkinson's to clear FDA in 10 years, Xadago has a narrower indication than Teva's Azilect and similar pricing.
The positive Phase II/III results for acoziborole have led researchers to claim that the goal of eliminating sleeping sickness by 2030 is now very much a reality.
The UK major has been building its cell therapy portfolio for about three years internally, oncology R&D chief Susan Galbraith tells Scrip, and the purchase of Neogene and its TCR-Ts targeting neoantigens in solid cancers is a logical step.